Company news
Dogwood Therapeutics, Inc. news in 2024
Dogwood Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
November 17, 2024
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
November 6, 2024
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
October 30, 2024
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 29, 2024
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 6, 2024
Virios Therapeutics Announces Second Quarter 2024 Financial Results
August 7, 2024
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 31, 2024
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
July 22, 2024
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 21, 2024
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 18, 2024
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 16, 2024
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 1, 2024
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
March 25, 2024
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
February 27, 2024
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
January 21, 2024
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
January 1, 2024
Calls in 2024
Decks in 2024
- Corporate Update (October 2024)
Corporate update · 19 slides · Oct 9, 2024